bioAffinity Technologies, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
6.78M
on 2026-06-30, from 362K on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-31 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
None
No S-3 or F-3 shelf on file in the last 30 months.
$5.8M
WallachBeth Capital, agreement of 2025-05-22. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
1.83M
Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $21.46. 10-Q ↗
Cash
0.8 quarters
$2.4M on 2026-06-30 ÷ $2.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-06-16 | Public offering incl. 2.96M pre-funded | 4,000,000 | $0.80 | $3.2M | 424B4 ↗ |
| 2025-10-08 | Public offering | 720,000 | $2.50 | $1.8M | 424B5 ↗ |
| 2025-10-08 | Registered direct offering | not read | not read | $1.8M | 8-K ↗ |
| 2025-09-29 | Public offering | not read | $2.50 | $4.8M | 424B4 ↗ |
| 2025-08-13 | Private placement | 6,714,780 | not read | $1.2M | 8-K ↗ |
| 2025-05-07 | Public offering incl. 2.37M pre-funded, with warrants at $0.35 | not read | not read | $3.2M | 424B4 ↗ |
| 2025-02-25 | Public offering | 1,801,944 | not read | not read | 424B5 ↗ |
| 2025-02-25 | Public offering | 2,724,230 | not read | not read | 424B5 ↗ |
| 2025-02-25 | Private placement | 1,302,082 | not read | $1.4M | 8-K ↗ |
Also on file: a 1-for-30 reverse split, 2025-09-17 8-K ↗ · a 1-for-15 reverse split, 2026-08-20 8-K ↗